12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Adaptimmune Ltd., GlaxoSmithKline deal

GlaxoSmithKline partnered with Adaptimmune to develop T cell receptor (TCR) therapies for cancer. The companies will co-develop Adaptimmune's lead program, an autologous TCR therapy targeting cancer/testis antigen 1B ( CTAG1B; NY-ESO-1), which is in Phase I/II testing for multiple myeloma (MM), melanoma, sarcoma and ovarian...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >